Bristol Myers Squibb (NYSE:BMY) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Bristol Myers Squibb (NYSE:BMY) had its target price upped by investment analysts at Royal Bank Of Canada from $60.00 to $64.00 in a research note issued on Friday,Benzinga reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target points to a potential downside of 1.86% from the stock’s previous close.

Several other research analysts have also weighed in on BMY. Weiss Ratings lowered Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 16th. Raymond James Financial restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Bank of America lowered their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Truist Financial reissued a “buy” rating and issued a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday. Nine equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $63.24.

Bristol Myers Squibb Trading Up 0.5%

Bristol Myers Squibb stock traded up $0.35 during midday trading on Friday, reaching $65.22. The stock had a trading volume of 7,463,982 shares, compared to its average volume of 12,234,030. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $65.66. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm has a market cap of $133.17 billion, a price-to-earnings ratio of 18.31, a PEG ratio of 0.18 and a beta of 0.23. The firm’s fifty day simple moving average is $57.90 and its two-hundred day simple moving average is $58.29.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company’s revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts anticipate that Bristol Myers Squibb will post 6.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds have recently bought and sold shares of BMY. Brighton Jones LLC lifted its position in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares during the last quarter. United Bank raised its stake in shares of Bristol Myers Squibb by 15.0% in the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 3,277 shares in the last quarter. Marshall Wace LLP acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth approximately $221,000. Finally, Nebula Research & Development LLC acquired a new stake in Bristol Myers Squibb in the 2nd quarter worth approximately $405,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q2 results exceeded expectations: Bristol Myers reported adjusted EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion versus estimates of $11.74 billion. Revenue increased 5.7% year over year, while EPS rose from $1.46 in the prior-year quarter. Bristol Myers raises 2026 forecast as Eliquis and newer medicines power results
• Positive Sentiment: 2026 outlook was raised: Management now expects full-year EPS of $6.75 to $7.00 and revenue of $49 billion to $50 billion, above consensus estimates of approximately $6.31 EPS and $47.3 billion in revenue. BMY Q2 earnings beat estimates and 2026 view raised
• Positive Sentiment: Growth products are gaining traction: Eliquis sales were a major contributor, while Camzyos, Reblozyl, Opdivo Qvantig, Breyanzi and other newer medicines helped the growth portfolio reach roughly 60% of revenue. Management also highlighted pipeline progress. Bristol-Myers Squibb Q2 2026 earnings call transcript
• Positive Sentiment: Analyst support improved: Truist reaffirmed its Buy rating and increased its price target from $65 to $70, implying additional upside from recent levels.
• Neutral Sentiment: Some analysts remain cautious, citing valuation after BMY’s recent rally and the need for continued execution to replace older products.
• Negative Sentiment: Risks remain: Legacy portfolio declines from patent expirations continue, while Opdivo declined and readouts for Milvexian and Cobenfy were delayed. Elevated put-option activity also indicates some investors are hedging downside risk.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.